Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. The company's management will engage in a fireside chat scheduled for February 6, 2025, at 1:30 p.m. ET.
Investors and interested parties can access a live webcast of the presentation through Mersana's website (www.mersana.com) in the Investors & Media section. The recorded session will remain available for approximately 90 days after the event.
Details
News Market Reaction – MRSN
The recorded move for MRSN in the trading session of this news was +8.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025 at 1:30 p.m. ET. A live webcast of this event will be available on the Investors & Media section of Mersana’s website at www.mersana.com, and an archived replay will be available for approximately 90 days following the event.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.